Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A⁎01 negative rhesus macaques

• Published in: Virology (New York, N.Y.) Vol. 374; no. 2; pp. 322 - 337
• Main Authors: Patterson, L. Jean, Beal, Jennifer, Demberg, Thorsten, Florese, Ruth H, Malkevich, Nina, Venzon, David, Aldrich, Kris, Richardson, Ersell, Kalyanaraman, V.S, Kalisz, Irene, Lee, Eun Mi, Montefiori, David C, Robey, Frank A, Robert-Guroff, Marjorie
• Format: Journal Article
• Language: English
• Published: 01.05.2008
• Subjects: Infectious Disease; Rhesus macaques; SHIV 89.6P challenge; HIV/SIV vaccines; Replicating adenovirus vectors; prime/boost
• ISSN: 0042-6822; 1096-0341
• DOI: 10.1016/j.virol.2007.12.037

Abstract Previously, replicating adenovirus type 5 host range (Ad5hr)-HIV/SIV recombinant priming in combination with SIV envelope boosting, resulted in significant, durable protection in 39% of rhesus macaques after SIVmac251 challenge. Both Env-specific antibody mediating ADCC, and cellular immunity correlated with protection. Here we evaluate the relative immunogenicities of novel HIV proteins and their contribution to protection in a SHIV89.6P model. All groups were primed with Ad-HIV env 89.6P , SIV gag 239 , and SIV nef 239 recombinants. One group was not boosted, one received HIV89.6P gp140ΔCFI protein, and one a novel HIV-1 poly-peptide “peptomer”. The HIV89.6P gp140ΔCFI protein in adjuvant strongly boosted Env-specific antibody and memory T cell responses in blood and tissue, resulting in significant reductions in acute and set point viremia. Macaques not boosted, showed a significant reduction in set point viremia, a full 32 weeks after the last Ad priming immunization. The HIV peptomer-boosted group showed a trend toward chronic viremia reduction, but was not protected.